当前位置: X-MOL 学术Prostate Cancer Prostatic. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.
Prostate Cancer and Prostatic Diseases ( IF 4.8 ) Pub Date : 2020-01-13 , DOI: 10.1038/s41391-020-0202-x
Salma Meziou 1, 2, 3 , Cassandra Ringuette Goulet 1, 2 , Hélène Hovington 1, 2 , Véronique Lefebvre 3 , Étienne Lavallée 1, 2 , Michelle Bergeron 1, 2 , Hervé Brisson 1, 2 , Audrey Champagne 1, 2 , Bertrand Neveu 1, 2 , Didier Lacombe 1, 2 , Jean-Mathieu Beauregard 1, 2, 4, 5 , François-Alexandre Buteau 4, 5 , Julie Riopel 3 , Frédéric Pouliot 1, 2
Affiliation  

BACKGROUND Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS Retrospective analysis was conducted for 94 patients diagnosed with a Gleason sum ≥8 adenocarcinoma of the prostate at biopsy between July 2011 and July 2014 who underwent 18F-FDG-PET/CT imaging before radical prostatectomy (RP). 18F-FDG-uptake in primary lesion was measured by a blinded reader using maximum standardised uptake value (SUVmax). GLUT1, GLUT12 and HK2 expression were blindly scored after immunohistochemistry on specimens RP by three pathologists. Correlations between GLUT1, GLUT12 and HK2, and SUVmax were assessed using Spearman's rank correlation test. Survival probabilities were based on the Kaplan-Meier method. RESULTS With a median follow-up of 4.5 years, 56% (n = 53) of patients had biochemical recurrence (BCR), 7% (n = 7) progressed to castration-resistant prostate cancer (CRPC) disease, 13% (n = 12) developed metastasis and 6% (n = 6) died. Correlation was found between GLUT1 expression and SUVmax level (r = 0.25, p = 0.02). In addition, SUVmax was significantly higher in tumours with high GLUT1 expression (n = 17, 5.74 ± 1.67) than tumours with low GLUT1 expression (n = 71, 2.68 ± 0.31, p = 0.004). Moreover, a significant association was found between GLUT1 expression levels and SUVmax level (p = 0.005), lymph node status (p = 0.05), volume of cancer (p = 0.01), CRPC disease progression (p = 0.02) and metastasis development (p = 0.04). No significant difference between GLUT12 and HEX2 expression and SUVmax have been found. CONCLUSIONS GLUT1 expression in PCa tumours correlates with 18F-FDG-uptake and poor prognostic factors. These results suggest that this transporter is involved in the molecular mechanism of 18F-FDG-uptake in high-risk PCa and raise interest in targeting metabolic dependencies of PCa cells as a selective anticancer strategy.

中文翻译:

GLUT1在高危前列腺癌中的表达:与18F-FDG-PET / CT和临床结果的相关性。

背景技术肿瘤18F-FDG摄取在高危和转移性前列腺癌(PCa)中具有预后价值。这项研究的目的是调查PCa的PET / CT成像中18F-FDG摄取的潜在葡萄糖代谢机制。方法回顾性分析2011年7月至2014年7月期间经活检确诊为Gleason总和≥8腺癌的94例患者,这些患者在根治性前列腺切除术(RP)之前接受了18F-FDG-PET / CT成像。通过盲法阅读器使用最大标准化摄取值(SUVmax)测量原发灶中18F-FDG摄取。免疫组化后,由三位病理学家对RP标本进行了GLUT1,GLUT12和HK2表达的盲目评分。使用Spearman秩相关检验评估GLUT1,GLUT12和HK2与SUVmax之间的相关性。生存概率基于Kaplan-Meier方法。结果中位随访时间为4.5年,其中56%(n = 53)的患者发生了生化复发(BCR),7%(n = 7)的患者发展为去势抵抗性前列腺癌(CRPC)疾病,13%(n = 12)发生转移,有6%(n = 6)死亡。发现GLUT1表达与SUVmax水平之间存在相关性(r = 0.25,p = 0.02)。此外,在具有高GLUT1表达的肿瘤中(n = 17,5.74±1.67),SUVmax明显高于具有低GLUT1表达的肿瘤(n = 71,2.68±0.31,p = 0.004)。此外,发现GLUT1表达水平与SUVmax水平(p = 0.005),淋巴结状态(p = 0.05),癌症体积(p = 0.01),CRPC疾病进展(p = 0.02)和转移发展之间存在显着相关性(p = 0.005)。 p = 0.04)。GLUT12和HEX2表达与SUVmax之间没有显着差异。结论PCa肿瘤中GLUT1的表达与18F-FDG摄取和不良预后相关。这些结果表明,该转运蛋白参与了高风险PCa中18F-FDG摄取的分子机制,并引起了人们对靶向PCa细胞代谢依赖性作为选择性抗癌策略的兴趣。
更新日期:2020-01-13
down
wechat
bug